Fight for precision medicine: Cancer sequencing saves lives.
Leads: Rep. Matsui (D-CA) and Rep. Bilirakis (R-FL) • Sen. Klobuchar (D-MN) and Sen. Wicker (R-MS)
Champion the life-changing potential of the Finn Sawyer Access to Cancer Testing ACT (Finn Sawyer A.C.T S. 642 / H.R. 1780) – a pioneering bill designed to revolutionize cancer care. Championed by the SHEPHERD Foundation, the Finn Sawyer A.C.T aims to extend multi-gene molecular diagnostics to all cancer patients - rare and common - at the time of diagnosis, enhancing treatment efficacy and curbing the use of unproductive therapies and unnecessary harmful side effects.
Each year, over 500,000 individuals are diagnosed with rare cancers, many of which lack contemporary care standards. The Finn Sawyer A.C.T will expand molecular diagnostic testing coverage for all cancer patients on Medicare, Medicaid, and CHIP by providing coverage at the time of diagnosis and beyond.
Broad-spectrum molecular diagnostics look at all of the genes in cancer. This approach can:
- Help identify new therapies for individual patients – even those who don’t have an existing treatment regimen because their cancer is rare or metastatic.
- Improve science’s understanding of under-researched cancers.
- Equalize access to modern therapies regardless of diagnosis.
Moreover, the bill fosters educational and awareness initiatives on genomic testing and the vital role of genetic counseling.
By supporting this legislation, you are fighting for its successful passage and contributing to a brighter future for innumerable cancer patients. Together, let's redefine cancer care and instill hope for ALL cancer patients – especially those grappling with rare, neglected, and difficult to treat cancers. Sign the petition now and become an advocate for the Finn Sawyer A.C.T. With your support, we can make a significant impact on the lives of cancer patients and their families
“Every single patient who has cancer, at any age, should have molecular diagnostics available at the time of their initial diagnosis. We finally have the technology to really fine-tune cancer diagnosis and treatment by identifying what an individual’s own tumor will respond to, and administer treatment specific to their tumor. Not only will this improve their chance at cure, but also avoid throwing a handful of chemotherapy drugs at every patient, most of them coming with devastating side effects and causing long-term issues to those lucky enough to survive. We simply cannot keep giving broad, outdated treatment regimens to every patient. Our cure rates are not adequate if we are still losing babies, kids and adults to cancer. We must do better for our patients - ALL patients - so this testing must be available to everyone.”
- Candace Granberg, M.D.